New Cabenuva approval in USA

Cabenuva (cabotegravir/rilpivirine) has been approved in the USA to treat HIV-1 in virologically suppressed adolescents who are 12 years of age or older and weigh at least 35kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either active ingredient.

The regimen was co-developed as part of a collaboration involving the GlaxoSmithKline (LSE: GSK) subsidiary ViiV Healthcare and the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ).

"We are bringing this younger population a first-of-its-kind HIV treatment that is dosed as few as six times a year"This approval marks the first time a long-acting HIV treatment is available for the adolescent population.